Anthropic and OpenEvidence Join Forces to Globalise Medical AI
Artificial intelligence startup Anthropic and a platform for medical knowledge OpenEvidence is collaborating to deliver AI-powered clinical decision support to physicians in regions lacking access to this technology, the companies stated on Tuesday. OpenEvidence addresses enquiries from medical professionals by utilising peer-reviewed research and established treatment guidelines. The platform is available at no cost to clinicians in the United States and Europe. The new initiative is a specialised version available to healthcare providers at no cost in numerous low- and middle-income countries, where restricted access to medical literature, specialist expertise, and continuing medical education can hinder patient care. Healthcare systems globally are investigating the potential of generative AI to mitigate the shortages of physicians and specialists.
Proponents contend that AI tools enable clinicians to efficiently sift through extensive medical information, whereas detractors warn that systems developed mainly on data from affluent nations may not accurately represent local practice environments. The initiative is being implemented across approximately 100 nations, such as Uganda, Angola, Sudan, Haiti, and Mongolia, as outlined in a list from OpenEvidence. “Access to medical knowledge shouldn’t depend on geography,” OpenEvidence founder Daniel Nadler said. Source reported last week that Anthropic has established a laboratory to conduct physical biology research as it advances its artificial intelligence initiatives in drug science. This development comes amid growing public concerns regarding the extent of AI’s influence, prompting some executives and lawmakers to advocate for a deceleration in progress.
Anthropic and OpenEvidence have not revealed the financial specifics of their collaboration. In August alone, US clinicians engaged with OpenEvidence 42 million times, as reported by Nadler. In 2026, several hundred million Americans will have received treatment from a physician who utilised OpenEvidence to assist in guiding their care, he stated. Anthropic’s technology will provide back-end support, while OpenEvidence will tailor the system to different regions, taking healthcare infrastructure into account, the companies said. “The technology itself has advanced so dramatically that the sort of structure needed for (bringing OpenEvidence to low-resource regions) is there, but the market incentives alone would not let it happen without this type of entrepreneurial, philanthropically minded work,” Anthropic president Daniela Amodei said.
Earlier this year, OpenEvidence announced its collaboration with health organisations in Rwanda and Botswana to tailor its tools for environments where disease patterns, diagnostic resources, and available treatments significantly diverge from those found in wealthier nations. “One hundred percent of what we are building for these places is context adaptive,” Nadler said. Even in regions where medical facilities lack continuous electricity, the majority of physicians possess smartphones, he noted, granting them access to high-quality medical information that, a decade prior, would have been exclusive to premier institutions such as the Mayo Clinic. Dr. Ahmed Bendary said expanding this access outside the United States and Europe “would be a tremendous leap forward, particularly in regions where institutional subscriptions to major medical journals are limited, making evidence-based, point-of-care tools even more vital.”
